BSH 2023 | Final analysis of the ALPINE trial: zanubrutinib vs ibrutinib in R/R CLL
Talha Munir
• 24 Apr 2023
In this video, Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares the results from a final analysis of the Phase III ALPINE trial (NCT03734016), which compared zanubrutinib versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Patients treated with zanubrutinib demonstrated a superior progression-free survival (PFS) and overall response rate (ORR) compared to those treated with ibrutinib. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
